MBX Biosciences, Inc.

Home
United States
Carmel, IN
MBX Biosciences, Inc.

At MBX Biosciences, our mission is to help people with endocrine and metabolic disorders live fuller and healthier lives. MBX is based in Carmel, Indiana.

We’re pioneering a pipeline of novel Precision Endocrine Peptides (PEPs) with clinically validated targets, established endpoints for regulatory approval, targeting significant unmet medical needs and large potential market opportunities. Our lead product candidate canvuparatide (MBX 2109), is in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, has recently compl

eted a Phase 1 trial and is in development for the treatment of post-bariatric hypoglycemia (PBH); and we also are developing an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development. To learn more, please visit the Company website at www.mbxbio.com.

06/01/2026

June 1 marks – an opportunity to spotlight hypoparathyroidism (HP) and the more than 100,000 people in the U.S. living with this rare endocrine disorder.

At MBX, we’re proud to partner with the HypoPARAthyroidism Association, Inc.], whose dedicated efforts support patients and families through education, community, research, and advocacy.

While awareness days play an important role, the need for progress in HP extends well beyond a single moment. We remain committed to advancing the science and leveraging our Precision Endocrine Peptide (PEP™) platform to help address the ongoing unmet needs of people living with HP.

05/20/2026

On , we celebrate the people behind scientific progress.

We are grateful to our team of talented researchers at MBX, and to the patients who inspire our work and drive clinical research forward every day.

Without their dedication, resilience, and trust, we would not be able to advance our mission of delivering innovative science to address unmet needs in endocrine and metabolic disorders.

Learn more about MBX’s clinical programs, including our planned Phase 3 trial investigating a once-weekly parathyroid hormone prodrug for chronic hypoparathyroidism: https://mbxbio.com/our-pipeline

04/24/2026

This , we join the European Society of Endocrinology (ESE) to raise awareness of the far‑reaching impact of hormone imbalances, which can drive chronic conditions like obesity and more than 400 rare endocrine diseases, including hypoparathyroidism.

At MBX, we are leveraging our Precision Endocrine Peptides™ (PEP™) Platform Technology to develop targeted therapies for rare endocrine disorders. Our PEPs are designed to address unmet needs and give hope to patients.

Learn more: mbxbio.com.

04/07/2026

This , MBX is proud to support the World Health Organization (WHO)'s call to .

We believe science has the power to help people living with endocrine and metabolic disorders live fuller, healthier lives. Guided by our commitment to innovation, our team of researchers is advancing new approaches aimed at making a meaningful difference in the treatment landscape for hypoparathyroidism, obesity, and post‑bariatric hypoglycemia.

Learn more about our commitment to science‑led innovation: mbxbio.com

03/04/2026

An estimated 4 billion people will be living with obesity by 2035.

We’re joining the World Obesity Federation to raise awareness of the experiences that people living with obesity encounter, including the unmet needs that remain with existing treatments.

With one candidate in Phase 1 clinical evaluation and two additional candidates anticipated, MBX is advancing a growing obesity pipeline built on our PEP platform, designed for once-monthly dosing and improved tolerability.

More information on obesity can be found in the World Obesity Day factsheet below.

10/24/2025

During MBX’s recent Together Week, we had the privilege of welcoming back Andrea Ligler — a powerful voice in the Hypoparathyroidism (HP) community and a patient advocate whose story continues to inspire. Andrea offered a deeply personal update on her journey with HP, sharing not only the medical realities but also the daily challenges and triumphs that come with managing this rare condition.

At MBX, our team understands the burden of HP — but it’s through courageous storytellers like Andrea that these lessons come to life. Her lived experience reminds us that behind every diagnosis is a person, a family, and a future shaped by resilience and hope. We remain steadfast in our mission to amplify patient voices and help people with endocrine and metabolic disorders live fuller and healthier lives.

Stories like Andrea’s don’t just inform us — they move us to act with greater empathy, urgency, and purpose.

10/15/2025

We’d like to thank everyone who joined us for our presentation, as well as express our gratitude to the HypoPARAthyroidism Association, Inc. for hosting a fantastic event this past weekend!

It is especially meaningful to see such strong engagement from the hypoparathyroidism patient community – the conversations and questions throughout the event reflected a shared optimism about the future of the HP treatment landscape.

09/22/2025

Hopeful news for people living with : The Phase 2 Avail clinical trial of our once-weekly parathyroid hormone (PTH) replacement therapy met its primary endpoint with a 63% responder rate at 12-weeks, and 79% responder rate in the open-label extension. The candidate was generally well-tolerated, and the findings are an important step forward in research for this rare and chronic condition.

We are so thankful to the patients, families, doctors, and research teams who made this study possible. Your dedication brings us closer to simpler, more effective care options.

Learn more about the data and next steps for the investigational once-weekly PTH replacement therapy: https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-once-weekly-canvuparatide-achieved

09/04/2025

We announced today that the first participant has been dosed in the Phase 1 trial of our Precision Endocrine Peptide (PEP) glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug for the treatment of .

Thank you to our talented team, whose dedication to improving the lives of patients affected by obesity brought this milestone to fruition.

Read the press release here: https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-doses-first-participant-phase-1-trial-mbx-4291

06/20/2025

During MBX’s latest Together Week, we were honored to host a fireside chat with Liz, who openly and honestly shared her journey with . Her story was a powerful reminder of the real people who can benefit from our platform — and the importance of listening to patient voices.

This conversation, along with others from patients with , deepens our understanding and drives our commitment to developing meaningful therapies.

At MBX Biosciences, we’re dedicated to improving the lives of those with and disorders. Hearing directly from patients inspires us to push forward, innovate with purpose, and never lose sight of who is at the center of our mission.

Address

Carmel, IN

Website

https://mbxbio.com/

Alerts

Be the first to know and let us send you an email when MBX Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to MBX Biosciences, Inc.:

Shortcuts

Want your business to be the top-listed Engineering Company in Carmel?